From USFDA
Zydus Cadila has received the final approval from the USFDA to market Acyclovir for Injection USP in strengths of 500 mg/vial and 100 mg/vial.Acyclovir for Injection USP which caters to anti-viral segment, will be produced at the group's formulations manufacturing facility at Moraiya, Ahmedabad.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
